It could indicate that the designed tracer has the potential of being translated for clinical implementation in order to reduce the percentage of tumor-positive resection margins during pancreatic cancer surgery, although future studies should focus on the comparison of conjugation strategies to other NIR fluorophores, thereby optimizing the design of this CEA targeted Nanobody tracer. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.